Amount of qualified sufferers: CDEC talked about the uncertainty in the volume of people with reasonably critical to significant hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical experts consulted by CADTH indicated that some patients who will be labeled as possessing moderate or reasonable condition might have a severe https://josueagjkm.blogsumer.com/34931892/facts-about-hemgenix-revealed